Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00602667 · OUTCOME

Neurocognitive Performance Related to Processing Speed as Measured by Visual Matching Standard Scores

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma · Source last updated 2026-05-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
score on a scale
Interval / dispersion
Standard Deviation
Time frame
Baseline, prior to maintenance therapy, completion of therapy, and 12 months, 24 months, 36 months, 48 months, and 60 months off therapy

What was measured

Scores measuring processing speed were obtained based on the visual matching standard score from the Woodcock Johnson III instrument. Higher scores indicate better performance. The normative mean is 100 with a standard deviation of 15.

Analysis population: Eligible patients with scores at any of the data collection timepoints were included. Sample sizes differ across timepoints as not all subjects had scores for all timepoints.

Groups in this outcome

Low-Risk Group

Patients with gross total resection (GTR)/no evidence of metastatic (M0) medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.

Intermediate-Risk Group

Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.

High-Risk Group

Patients with central nervous system (CNS) metastatic disease will receive induction chemotherapy and high-risk therapy.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Low-Risk Group23
Intermediate-Risk Group49
High-Risk Group9

Reported measurements

Baseline

Analysis denominator · Participants

GroupSource count
Low-Risk Group1
Intermediate-Risk Group6
High-Risk Group1
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group119.0Not reportedNot reportedNot reportedNot reported
Intermediate-Risk Group96.511.0Not reportedNot reportedNot reported
High-Risk Group107.0Not reportedNot reportedNot reportedNot reported
Prior to Maintenance Therapy

Analysis denominator · Participants

GroupSource count
Low-Risk Group1
Intermediate-Risk Group8
High-Risk Group2
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group89.0Not reportedNot reportedNot reportedNot reported
Intermediate-Risk Group97.612.3Not reportedNot reportedNot reported
High-Risk Group109.52.1Not reportedNot reportedNot reported
Completion of Therapy

Analysis denominator · Participants

GroupSource count
Low-Risk Group4
Intermediate-Risk Group13
High-Risk Group0
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group105.320.2Not reportedNot reportedNot reported
Intermediate-Risk Group100.215.2Not reportedNot reportedNot reported
12 Months Off Therapy

Analysis denominator · Participants

GroupSource count
Low-Risk Group5
Intermediate-Risk Group17
High-Risk Group1
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group96.89.8Not reportedNot reportedNot reported
Intermediate-Risk Group93.113.3Not reportedNot reportedNot reported
High-Risk Group71.0Not reportedNot reportedNot reportedNot reported
24 Months Off Therapy

Analysis denominator · Participants

GroupSource count
Low-Risk Group12
Intermediate-Risk Group26
High-Risk Group3
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group98.416.6Not reportedNot reportedNot reported
Intermediate-Risk Group90.215.3Not reportedNot reportedNot reported
High-Risk Group89.313.3Not reportedNot reportedNot reported
36 Months Off Therapy

Analysis denominator · Participants

GroupSource count
Low-Risk Group11
Intermediate-Risk Group25
High-Risk Group4
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group101.615.8Not reportedNot reportedNot reported
Intermediate-Risk Group89.720.2Not reportedNot reportedNot reported
High-Risk Group89.812.4Not reportedNot reportedNot reported
48 Months Off Therapy

Analysis denominator · Participants

GroupSource count
Low-Risk Group13
Intermediate-Risk Group26
High-Risk Group3
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group93.223.9Not reportedNot reportedNot reported
Intermediate-Risk Group87.614.7Not reportedNot reportedNot reported
High-Risk Group78.717.0Not reportedNot reportedNot reported
60 Months Off Therapy

Analysis denominator · Participants

GroupSource count
Low-Risk Group13
Intermediate-Risk Group17
High-Risk Group1
Values in score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Low-Risk Group86.336.2Not reportedNot reportedNot reported
Intermediate-Risk Group84.617.1Not reportedNot reportedNot reported
High-Risk Group65.0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        119.0
      2. group Id
        OG001
        spread
        11.0
        value
        96.5
      3. group Id
        OG002
        value
        107.0
    denoms
    1. counts
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        6
      3. group Id
        OG002
        value
        1
      units
      Participants
    title
    Baseline
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        89.0
      2. group Id
        OG001
        spread
        12.3
        value
        97.6
      3. group Id
        OG002
        spread
        2.1
        value
        109.5
    denoms
    1. counts
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        8
      3. group Id
        OG002
        value
        2
      units
      Participants
    title
    Prior to Maintenance Therapy
  3. categories
    1. measurements
      1. group Id
        OG000
        spread
        20.2
        value
        105.3
      2. group Id
        OG001
        spread
        15.2
        value
        100.2
    denoms
    1. counts
      1. group Id
        OG000
        value
        4
      2. group Id
        OG001
        value
        13
      3. group Id
        OG002
        value
        0
      units
      Participants
    title
    Completion of Therapy
  4. categories
    1. measurements
      1. group Id
        OG000
        spread
        9.8
        value
        96.8
      2. group Id
        OG001
        spread
        13.3
        value
        93.1
      3. group Id
        OG002
        value
        71.0
    denoms
    1. counts
      1. group Id
        OG000
        value
        5
      2. group Id
        OG001
        value
        17
      3. group Id
        OG002
        value
        1
      units
      Participants
    title
    12 Months Off Therapy
  5. categories
    1. measurements
      1. group Id
        OG000
        spread
        16.6
        value
        98.4
      2. group Id
        OG001
        spread
        15.3
        value
        90.2
      3. group Id
        OG002
        spread
        13.3
        value
        89.3
    denoms
    1. counts
      1. group Id
        OG000
        value
        12
      2. group Id
        OG001
        value
        26
      3. group Id
        OG002
        value
        3
      units
      Participants
    title
    24 Months Off Therapy
  6. categories
    1. measurements
      1. group Id
        OG000
        spread
        15.8
        value
        101.6
      2. group Id
        OG001
        spread
        20.2
        value
        89.7
      3. group Id
        OG002
        spread
        12.4
        value
        89.8
    denoms
    1. counts
      1. group Id
        OG000
        value
        11
      2. group Id
        OG001
        value
        25
      3. group Id
        OG002
        value
        4
      units
      Participants
    title
    36 Months Off Therapy
  7. categories
    1. measurements
      1. group Id
        OG000
        spread
        23.9
        value
        93.2
      2. group Id
        OG001
        spread
        14.7
        value
        87.6
      3. group Id
        OG002
        spread
        17.0
        value
        78.7
    denoms
    1. counts
      1. group Id
        OG000
        value
        13
      2. group Id
        OG001
        value
        26
      3. group Id
        OG002
        value
        3
      units
      Participants
    title
    48 Months Off Therapy
  8. categories
    1. measurements
      1. group Id
        OG000
        spread
        36.2
        value
        86.3
      2. group Id
        OG001
        spread
        17.1
        value
        84.6
      3. group Id
        OG002
        value
        65.0
    denoms
    1. counts
      1. group Id
        OG000
        value
        13
      2. group Id
        OG001
        value
        17
      3. group Id
        OG002
        value
        1
      units
      Participants
    title
    60 Months Off Therapy
denoms
  1. counts
    1. group Id
      OG000
      value
      23
    2. group Id
      OG001
      value
      49
    3. group Id
      OG002
      value
      9
    units
    Participants
description
Scores measuring processing speed were obtained based on the visual matching standard score from the Woodcock Johnson III instrument. Higher scores indicate better performance. The normative mean is 100 with a standard deviation of 15.
dispersion Type
Standard Deviation
groups
  1. description
    Patients with gross total resection (GTR)/no evidence of metastatic (M0) medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.
    id
    OG000
    title
    Low-Risk Group
  2. description
    Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.
    id
    OG001
    title
    Intermediate-Risk Group
  3. description
    Patients with central nervous system (CNS) metastatic disease will receive induction chemotherapy and high-risk therapy.
    id
    OG002
    title
    High-Risk Group
param Type
MEAN
population Description
Eligible patients with scores at any of the data collection timepoints were included. Sample sizes differ across timepoints as not all subjects had scores for all timepoints.
reporting Status
POSTED
time Frame
Baseline, prior to maintenance therapy, completion of therapy, and 12 months, 24 months, 36 months, 48 months, and 60 months off therapy
title
Neurocognitive Performance Related to Processing Speed as Measured by Visual Matching Standard Scores
type
SECONDARY
unit Of Measure
score on a scale

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice